Qim­ing-backed CAN­bridge gets its Hong Kong IPO as Nas­daq slow­down prompts re­newed mar­ket analy­sis

Though IPO ac­tiv­i­ty has slowed in the US sig­nif­i­cant­ly, a Qim­ing Ven­ture-backed biotech took the pub­lic leap in a Hong Kong de­but Fri­day.

CAN­bridge Phar­ma­ceu­ti­cals …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER